Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior)...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez, A., Brun, L. R., Salerni, H., Costanzo, P. R., González, D., Bagur, A., Oliveri, B., Zanchetta, M. B., Farías, V., Maffei, L., Premrou, V., Mansur, José Luis, Larroudé, M. S., Sarli, M. A., Rey, P., Ulla, M. R., Pavlove, M. M., Karlsbrum, S., Brance, M. L.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:Argentina
Institución:Universidad Nacional de La Plata
Repositorio:SEDICI (UNLP)
Idioma:inglés
OAI Identifier:oai:sedici.unlp.edu.ar:10915/151985
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/151985
Access Level:acceso abierto
Palabra clave:Medicina
denosumab
bone mineral density
bone turnover markers
osteoporosis
Descripción
Sumario:The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

Similares en LA Referencia